Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study.
Collignon A, Hospital MA, Montersino C, Courtier F, Charbonnier A, Saillard C, D'Incan E, Mohty B, Guille A, Adelaïde J, Carbuccia N, Garnier S, Mozziconacci MJ, Zemmour C, Pakradouni J, Restouin A, Castellano R, Chaffanet M, Birnbaum D, Collette Y, Vey N. Collignon A, et al. Blood Cancer J. 2020 Jun 3;10(6):64. doi: 10.1038/s41408-020-0330-5. Blood Cancer J. 2020. PMID: 32488055 Free PMC article. Clinical Trial.
Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome.
Bouchacourt B, Hospital MA, Zemmour C, Rey J, d'Incan E, Charbonnier A, Mohty B, Saillard C, Bonnet S, Collignon A, Gelsi-Boyer V, Mozziconacci MJ, Blaise D, Vey N. Bouchacourt B, et al. Among authors: collignon a. Ann Hematol. 2020 Apr;99(4):773-780. doi: 10.1007/s00277-020-03922-w. Epub 2020 Feb 22. Ann Hematol. 2020. PMID: 32088745
Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore).
Bris PN, Gauchez P, Devillier R, Galicier L, Collignon A, Piana G, Poizat F, Faucher M, Hospital MA, Vey N, Gonzalez F, Servan L, Chow-Chine L, Sannini A, Mokart D, Saillard C, Bisbal M. Bris PN, et al. Among authors: collignon a. Br J Haematol. 2022 Oct;199(1):106-116. doi: 10.1111/bjh.18382. Epub 2022 Aug 15. Br J Haematol. 2022. PMID: 35968907 Free PMC article.
Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas.
Montes de Oca C, Castagna L, De Philippis C, Bramanti S, Schiano JM, Pagliardini T, Collignon A, Harbi S, Mariotti J, Granata A, Maisano V, Furst S, Legrand F, Chabannon C, Carlo-Stella C, Santoro A, Blaise D, Devillier R. Montes de Oca C, et al. Among authors: collignon a. Biol Blood Marrow Transplant. 2020 Dec;26(12):2299-2305. doi: 10.1016/j.bbmt.2020.08.014. Epub 2020 Aug 19. Biol Blood Marrow Transplant. 2020. PMID: 32822845 Free article.
GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation.
Dachy F, Furst S, Calmels B, Pagliardini T, Harbi S, Bouchacourt B, Calleja A, Lemarie C, Collignon A, Morel G, Legrand F, Bekrieva E, Granata A, Weiller PJ, Chabannon C, Schiano JM, Vey N, Blaise D, Devillier R. Dachy F, et al. Among authors: collignon a. Bone Marrow Transplant. 2023 Nov;58(11):1179-1181. doi: 10.1038/s41409-023-02033-0. Epub 2023 Aug 9. Bone Marrow Transplant. 2023. PMID: 37558780 No abstract available.
Impact of CD34-positive cell dose on outcome after peripheral blood stem cell allogeneic transplantation prepared with ATG-based reduced intensity conditioning regimen.
Collignon A, Calmels B, Harbi S, Fürst S, Granata A, Faucher C, Lemarie C, Weiller PJ, Chabannon C, Blaise D, Devillier R. Collignon A, et al. Am J Hematol. 2017 Apr;92(4):E57-E59. doi: 10.1002/ajh.24661. Epub 2017 Feb 24. Am J Hematol. 2017. PMID: 28133837 Free article. No abstract available.
Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.
Quinquenel A, Godet S, Dartigeas C, Ysebaert L, Dupuis J, Ohanyan H, Collignon A, Gilardin L, Lepretre S, Dilhuydy MS, Vignon M, de Guibert S, Dmytruk N, Durot E, Ghez D, Roos Weil D, Béné MC, Toussaint E, Merabet F, Lévy V, Delmer A, Aurran T. Quinquenel A, et al. Among authors: collignon a. Am J Hematol. 2019 Jul;94(7):E183-E185. doi: 10.1002/ajh.25480. Epub 2019 Apr 11. Am J Hematol. 2019. PMID: 30945328 Free article. Clinical Trial. No abstract available.
Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study.
Jourdes A, Cellerin E, Touzeau C, Harel S, Denis B, Escure G, Faure E, Jamard S, Danion F, Sonntag C, Ader F, Karlin L, Soueges S, Cazelles C, de La Porte des Vaux C, Frenzel L, Lanternier F, Brousse X, Cazaubiel T, Berger P, Collignon A, Blot M, Pieragostini A, Charles M, Chaleteix C, Redor A, Roland V, Cartau T, Macro M, Chalopin T, Vallet N, Perrot A, Martin-Blondel G; G2I and the IFM networks. Jourdes A, et al. Among authors: collignon a. Clin Microbiol Infect. 2024 Jun;30(6):764-771. doi: 10.1016/j.cmi.2024.02.023. Epub 2024 Mar 1. Clin Microbiol Infect. 2024. PMID: 38432433 Free article.
178 results